DermTech (NASDAQ:DMTK) reported Q4 EPS of ($0.93), $0.03 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $3 million versus the consensus estimate of $2.55 million.
DermTech (NASDAQ:DMTK) reported Q4 EPS of ($0.93), $0.03 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $3 million versus the consensus estimate of $2.55 million.